Skip to main content
Matthew Witkowski on Muck Rack

Matthew Witkowski

As seen in: Cell Press

Get in touch with Matthew

Contact Matthew, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Articles

RAF-independent MEK mutations drive refractory histiocytic neoplasms but respond to ERK inhibition

|
By Eli L. Diamond, Jean-François Emile, Takeshi Fujino, Julien Haroche, Maxim I. Maron, Alexander Lewis Verified, Jahan A. Rahman, Anne Reiner, Dana F. Bossert, Marc K. Rosenblum, Mariko Yabe, Kseniya Petrova-Drus, Jasmine H. Francis, Veronica Rotemberg, Raajit Rampal, Sarah Paiji Yoo, Anthony F. Daniyan, sonia mahajan, Vaios Hatzoglou, Robert Young, Gary A. Ulaner, Wiebke Rösler, Oshrat Hershkovitz-Rokah, Ofer Shpilberg, Roei D. Mazor, Michael Singer Verified, M. Adriana Cuibus, Salima Benbarche, Pu Zhang, Nina Fox, Cynthia Castro, Matthew Witkowski, Fleur Cohen-Aubart, Louis Terriou, Maher Hanoun, Nicolas Schleinitz, Gabriela Sosa, Timo Hautala, Neal Rosen, Omar Abdel-Wahab Verified, Benjamin H. Durham, Kenyon Weis, Steven Tittley
| Cell Press Verified
Keywords BRAF cobimetinib Erdheim-Chester disease histiocytoses Langerhans cell histiocytosis macrophage MEK ERK trametinib ulixertinib Introduction Histiocytic neoplasms (histiocytoses) are a diverse group of clonal hematopoietic disorders defined by the accumulation of macrophages, dendritic cells, or monocyte-derived cells in various tissues.1 Histiocytoses subtypes include Langerhans cell histiocytosis (LCH), Erdheim-Chester disease (ECD), juvenile xanthogranuloma (JXG),...
Open in Who Shared Issue with article?
See all 1 articles